Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
An Extended time of Self-Reflection: Self-awareness through Journaling - 2Farmers worry about rising cost of fertiliser
- 3German Winemakers Rewrite The Rules Of Riesling In A Warming World
- 4Norovirus is spreading earlier again this year, wastewater data shows
- 5I decided to become a single mother by choice. I wasn't ready to stop dating.
- See the first close-up photos of the moon from NASA's Artemis II mission
- 'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off
- How to disinfect if the stomach bug hits your home
- Creative Style: 10 Architects Reclassifying the Business
- Figure out How to Get a good deal on Your Rooftop Substitution Venture
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- Asia's Noteworthy Destinations: A Voyager's Aide
- 6 Top Computer game Control center
